Obstructive sleep apnea, commonly known as OSA, affects millions of people worldwide and remains one of the most underdiagnosed sleep disorders today. Many patients struggle with continuous positive airway pressure therapy, also called CPAP or PAP therapy, because of discomfort, inconvenience, or poor long term adherence. A new investigational oral medication called AD109 may offer a different option for people who cannot tolerate traditional sleep apnea treatment.
A recently published phase 3 clinical trial called SynAIRgy evaluated the effectiveness and safety of AD109 in adults with mild to severe obstructive sleep apnea. The findings suggest the once daily oral tablet could significantly improve breathing interruptions and oxygen levels during sleep.
AD109 is an investigational oral medication that combines two drugs:
The therapy is designed to improve upper airway muscle tone during sleep. Researchers believe this may help prevent airway collapse, which is the primary cause of obstructive sleep apnea.
Unlike CPAP machines that mechanically keep airways open, AD109 targets the neuromuscular dysfunction associated with OSA. This makes it one of the first potential oral medications developed specifically for sleep apnea treatment.
The study was published in the American Thoracic Society journal, the American Journal of Respiratory and Critical Care Medicine.
Current OSA treatments have several limitations. CPAP therapy is effective for many patients, but long term adherence remains a major challenge. Some people discontinue treatment within the first year due to discomfort, noise, mask irritation, or sleep disruption.
Researchers estimate that obstructive sleep apnea affects nearly one billion people globally. Many patients remain untreated, increasing the risk of:
An effective oral medication could fill a major treatment gap for patients unwilling or unable to use PAP therapy.
The SynAIRgy trial was a randomized, double blind, placebo controlled phase 3 study conducted across 69 medical centers in the United States and Canada.
Researchers enrolled 646 adults with mild to severe obstructive sleep apnea who either:
Participants were randomly assigned to receive either AD109 or a placebo for 26 weeks.
The study population included a broad range of patients:
This diversity strengthens the reliability and generalizability of the findings.
The primary endpoint measured changes in the apnea hypopnea index, also known as AHI. AHI tracks how often breathing pauses or becomes shallow during sleep.
At 26 weeks, AD109 produced meaningful improvements:
Researchers also found improvements as early as week four.
Many participants shifted from moderate sleep apnea into the mild category after treatment.
AD109 also improved oxygen related sleep metrics, including:
These measures are important because repeated oxygen drops during sleep are associated with increased cardiovascular risk and long term health complications.
The improvements suggest AD109 may reduce harmful overnight oxygen deprivation in patients with OSA.
The study also evaluated fatigue and sleep impairment using patient reported questionnaires.
Researchers found:
This suggests some symptomatic benefits may exist, especially in patients with significant daytime sleepiness.
Like many medications, AD109 caused side effects in some participants.
The most common adverse events included:
About 21% of participants receiving AD109 discontinued treatment because of side effects, compared with 3.1% in the placebo group.
Importantly:
Researchers noted that future studies may evaluate lower dosing strategies to improve tolerability.
At this stage, AD109 is still investigational and has not yet received regulatory approval. However, experts believe it could become an important alternative for patients who cannot use PAP therapy.
The medication may not fully replace CPAP for every patient, especially those with severe disease. However, the oral therapy could offer several advantages:
Researchers emphasized that AD109 targets one of the root neurological causes of obstructive sleep apnea rather than simply managing symptoms mechanically.
The SynAIRgy study stands out because of its:
Many earlier sleep apnea drug studies were smaller or shorter in duration.
The results support growing interest in pharmacologic treatment options for sleep apnea, particularly for patients who struggle with traditional therapy.
Additional phase 3 trials and regulatory review will likely determine whether AD109 becomes commercially available.
Researchers still need to better understand:
Despite these unanswered questions, the trial represents one of the most promising developments in oral sleep apnea treatment in recent years.
The SynAIRgy phase 3 trial suggests AD109 may become a valuable new option for adults with obstructive sleep apnea who cannot tolerate PAP therapy. The once daily oral medication significantly improved breathing interruptions and oxygenation during sleep across a broad patient population.
Although side effects and discontinuation rates remain important concerns, the study highlights the growing shift toward personalized and more accessible sleep apnea therapies.
If future studies confirm these results and regulators approve the medication, AD109 could reshape the treatment landscape for millions of people living with untreated or undertreated obstructive sleep apnea.
“Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy)” published in the American Journal of Respiratory and Critical Care Medicine on May 18, 2026.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. AD109 is currently an investigational medication and may not yet be approved by regulatory authorities. Always consult a qualified healthcare professional regarding sleep apnea symptoms, treatment decisions, or medication use.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.